Date: 2016-01-08
Type of information: Construction of new premises
Compound:
Company: WuXi AppTec (China)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On January 8, 2016, WuXi AppTec, a leading open access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced that it has started The biologics development center will utilize WuXi’s proprietary CHO cell line platform to develop robust fed-batch and perfusion processes to meet demanding processing needs. The co-located cGMP clinical manufacturing facilities will support four concurrent campaigns using 3x2000L fed-batch and 2x500L perfusion bioreactors.
construction of a state-of-the-art integrated biologics solution center at the company’s headquarters in Shanghai. The company plans to invest a total of $120 million in this dedicated, 250,000-square-foot facility, which will be operational in 2017 and accommodate 800 scientists. The facility will provide integrated solutions from ideas to the clinic for biologics discovery, development, and clinical manufacturing on a consolidated campus.
The biologics discovery center will utilize the state-of-the-art OmniRat™ platform in collaboration with Open Monoclonal Technology, Inc., and in-house proprietary phage display libraries to enable global clients to discover conventional mAbs, bi-specific mAbs and antibodydrug conjugates.
Financial terms:
Latest news:
